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Different hydrophobic glycoproteins are associated to native biliary vesicles, which are the major carrier of biliary cholesterol. Some of these proteins 
promote cholesterol crystallization, a key step in cholesterol gallstone formation. This study was specifically conducted to identify the 130 kDa 
biliary vesicle-associated glycoprotein and to determine its in vitro effect on the cholesterol crystal formation time. The 130 kDa vesicular 
glycoprotein was identified as aminopeptidase-N by amino acid sequencing and specific enzymatic assay. Polyclonal antibodies raised against 
aminopeptidase-N allowed us to determine its concentration in human hepatic bile, which varied from 17.3 to 57.6pglml. Aminopeptidase-N showed 
a concentration-dependent cholesterol crystallization activity when it was added to supersaturated model bile at aconcentration range usually found 
in native bile. Because of this promoting effect on in vitro cholesterol crystal formation, we suggest that bihary aminopeptidase-N may play a critical 
role in the pathogenesis of cholesterol gallstone disease. 
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1. INTRODUCTION 
Cholesterol crystallization from supersaturated 
human bile is a key step in the pathogenesis of cholest- 
erol gallstone disease [ 1,2]. Recently, different biliary 
proteins have been described with cholesterol nuclea- 
tion i~uen~ng activity. Mucin [3], i~unoglobulins 
[4] and other small molecular weight glycoproteins, 
such as a 130 kDa glycoprotein [5], presumably amin- 
opeptidase-N [6], flbronectin [7], phospholipase C [8] 
and a-l-acid glycoprotein [9], have been reported as 
pronucleating biliary proteins. However, the real pa- 
thophysiological significance of these cholesterol pro- 
nucleating factors still remains to be defined. 
Nowadays, there is general agreement hat cholest- 
erol crystal formation occurs from biliary vesicles [lO- 
121, the major carrier of biliary cholesterol [13-161. 
Cholesterol crystals probably nucleate as a consequence 
of aggregation and fusion of these cholesterol-~ch vesi- 
cles [17,18]. Thus, nucleation promoting factors must 
presumably be interacting with the vesicular carriers to 
induce biliary cholesterol crystallization. 
To elucidate the major protein factors involved in 
accelerated cholesterol nucleation time of bile from pa- 
tients with gallstones, we have been interested in study- 
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ing the association of putative pronucleating proteins 
with native biliary vesicles. First, we isolated and puri- 
fied native biliary vesicles from cholesterol gallstone 
patients [19]. These vesicles were mainly composed of 
cholesterol and phospholipids, but also contained a 
characteristic and well-defined protein profile [19,20], 
including some biliary-s~i~c hydrophobic glycopro- 
teins (130, 114, 86 and 62-67 kDa molecular weights) 
[20]. In addition, we demonstrated that lipid solutions 
containing the vesicle-associated proteins have in vitro 
cholesterol pronucleating activity [19], which was de- 
pendent of protein concentration, but not related to 
lipid composition. Furthermore, we have shown that 
the 130, 114, 62-67 kDa vesicular glycoproteins ignifr- 
cantly decrease the cholesterol nucleation time of artifi- 
cial model bile [20]. 
The aims of this study were to isolate and identify the 
vesicle-associated 130 kDa glycoprotein, to quantitate 
its con~ntration in human hepatic bile and to test its 
in vitro cholesterol pronucleating activity at concentra- 
tions usually found in native bile. 
2. MATERIALS AND METHODS 
2.1. Bile sampling 
Hepatic bile was obtained from cholesterol gallstone patients 
through indwelling T-tubes after cholescystectomy and choledocot- 
omy. Bile samples were collected in sterile tubes containing 0.05% 
chloramphenicol, 3 mM sodium azide, 0.2 mM thymerosal, 1 mM 
PMSF and 1 mM leupeptin as preservatives. Bile was immediately 
processed for biliary vesicle isolation. 
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2.2. Isolation and purification of biliary vesicles 
Firstly, bile samples werer centrifuged at 10,000 x g for 10 min and 
filtered through l-pm filters. Then, 16% metrizamide (Sigma Chemi- 
cals Co. St. Louis, MO, USA) was directly dissolved in bile and 
bile-metrizamide mixture was ultracentrifuged at 160,000 x g for 200 
min at 10°C to isolate biliary vesicles [21]. The vesicular fraction in 
the top of the centrifuge tube was further purified by two sequential 
gel filtration chromatographic steps, as previously described [19,20]. 
2.3. Gel electrophoresis 
Proteins were precipitated with 8% (w/v) trichloroacetic acid from 
whole bile, micellar fraction and purified vesicles as required and, 
then, delipidated using ethanol/diethylether (1:3, v/v) prior to electro- 
phoresis. Proteins were resuspended in reducing sample buffer and 9% 
SDS-PAGE was performed by standard techniques [22]. Gels were 
stained with Coomassie brilliant blue or silver staining. 
2.4. Isolation and renaturation of the 130 kDa vesicular glycoprotein 
The 130 kDa glycoprotein associated to purified biliary vesicles was 
isolated by electroelution from preparative polyacrylamide gels. The 
Coomassie blue-stained 130 kDa protein band was excised from gels. 
The gel Coomassie blue-stained 130 kDa protein band was excised 
from gels. The gel slices were transferred to a dialysis bag containing 
192 mM glycine and 25 mM Tris-HCl (pH 7.4) and, then, electroelu- 
tion was performed overnight at 50 mA in a horizontal chamber with 
96 mM glycine and 12.5 mM Tris-HCl @H 7.4). The electroeluted 
protein was concentrated by ultrafiltration and, finally, lyophilized. 
The purification of the 130 kDa vesicular glycoprotein was evaluated 
by re-electrophoresis as described above. 
The 130 kDa protein was renaturated after preparative SDS-PAGE, 
as previously described [23,24], to obtain the protein under native 
conditions for cholesterol crystallization assays. The region of the 
polyacrylamide gels containing the 130 kDa polypeptide was excised 
and eluted by diffusion in elution buffer (0.1% SDS, 0.1 mM EDTA, 
5 mM DTT, 150 mM NaCl and 50 mM Tris-HCl, pH 7.4). After 
overnight elution, the SDS was removed from the protein by acetone 
precipitation and the precipitated protein was resuspended in 6 M 
guanidine hydrochloride. Subsequently, removal of guanidine was 
performed by P-10 Bio-Rad gel filtration as previously reported [24]. 
2.5. Amino acid sequencing of the 130 kDa vesicular protein 
The 130 kDa glycoprotein purified from biliary vesicles was re- 
electrophoresed. Then, it was electroblotted to a polyvinylidine dif- 
luoride (PVDF) membrane in appropriate transfer buffer (10% meth- 
anol, 10 mM CAPS, pH 10.0). The blotted protein was evidenced by 
Coomassie blue and the band was cut out for amino acid sequencing. 
The protein was directly sequenced from the PDVF membrane using 
an Applied Biosystems gas-phase sequencer equipped with an on-line 
PTH analyzer. The amino acid sequence of the 130 kDa protein was 
compared with the Protein Identification Resource National Biome- 
dial Research Foundation (USA) data base. 
2.6. Antibody preparation 
The purified 130 kDa protein was emulsified with complete Fre- 
und’s adjuvant and 50 pg was injected in the popliteal lymph node of 
white females New Zealand rabbits. Intradetmal booster doses (100 
pg) were administered weekly for three times. Blood samples from the 
marginal ear vein were taken to detect the production of specific 
antibodies by immunoblotting [25]. 
2.7. Quantitative immunoblotting 
The concentration of the 130 kDa glycoprotein was measured by 
quantitative immunoblotting in hepatic bile. Five microliters of differ- 
ent hepatic bile samples were processed in duplicate for reducing 
SDS-PAGE [22] and immunoblotting [25]. The rabbit anti-130 kDa 
protein polyclonal antibody was used as the primary antibody. Ad- 
sorbed immunoglobulins were detected by using Protein A-coupled 
alkaline phosphatase and the color reaction was developed with 3- 
bromo4chloro-5-indolyl-phosphate and nitroblue tetrazolium as 
substrates. Quantitation was performed by densitometry (Shimadzu, 
Tokyo, Japan) of immunoblotted bile samples in comparison with 
previously known amounts of purified 130 kDa vesicular glycoprotein 
as a standard. The densitometric measurements of these standards 
gave a linear correlation curve within the protein concentrations em- 
ployed in the procedure and all native bile samples were within this 
range. 
2.8. Cholesterol observation time assays 
Crystal observation time (the time interval between a bile sample 
was cleared of crystals and the first detection of typical cholesterol 
crystals) of native hepatic bile was performed by polarizing micros- 
copy. The effect of put&d and renaturated 130 kDa vesicular 
glycoprotein on cholesterol crystal formation of supersaturated model 
bile was determined by the method described by Groen et al. [5]. After 
renaturation, the 130 kDa protein was filtered through 0.22~pm filters 
and aliquots were added to artificial bile to obtain an increasing 
protein concentration in the assays. Cholesterol nucleation assays 
were performed in triplicate for each protein concentration. The time 
of crystal appearance was observed as described above. In all studies, 
control assays were performed by adding the same volume aliquots of 
the renaturating solution, without protein, to model bile. These con- 
trol experiments did not show signhicant modifications in the cholest- 
erol crystal appearance time of the original model bile. 
2.9. Chemical analysis 
Cholesterol, phospholipids, bile salts and total protein concentra- 
tion in hepatic bile was determined as previously described [21,26]. The 
cholesterol saturation index was calculated using Carey’s critical tables 
[27]. The renaturation of the vesicle-associated aminopeptidase-N was 
tested by assaying its enzymatic activity [28]. 
2.10 Statistical analysis 
The correlation coefficients and the statistical significance of the 
correlations were performed on a Macintosh computer, using SYS- 
TAT analytic software. P values < 0.05 were considered significant. 
3. RESULTS 
Hepatic bile was obtained from patients with cholest- 
erol gallstones. The lipid and protein composition of 
these bile samples are presented in Table I. Each sample 
was separately processed to obtain purified 130 kDa 
vesicular glycoprotein. 
Firstly, isolated and purified biliary vesicles were pre- 
pared by ultracentrifugation and, subsequently, gel fil- 
tration chromatography, as previously described [ 19- 
Table I 
Lipid and protein composition, cholesterol saturation and nucleation 
time of human hepatic bile from cholesterol gallstone patients 
Hepatic bile 




Cholesterol saturation (%) 
Cholesterol nucleation time (days) 
Total protein concentration (mg/ml) 
Aminopeptidase-N concentration (mg/ml) 
21 + 5.7 
4.9 f 0.7 
2.3 f 0.8 
199 f 59 
12 + 5 
5 f 1.8 
0.04 + 0.01 
Bile was obtained from six patients with T-tube bile fistula, one week 
after surgery. Values represent he mean f 1 S.D. 
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Fig. 1. SDS-polyacrylamide gel electrophoresis of native bile, micellar 
and vesicular fractions and purified 130 kDa vesicular glycoprotein. 
Lane 1, whole native bile; lane 2, biliary micellar fraction; lane 3, 
purified biliary vesicles; lane 4, purified 130 kDa vesicular glycopro- 
tein. 5Opg of total protein were applied to each lane. Protein molecular 
weight markers are indicated at the left margin. 
211. The major composition of purified biliary vesicles 
were cholesterol and phospholipids (molar ratio of 1.1) 
(result not shown). A minor (0.8 f 0.2, w/w), but con- 
stant, protein component was always detected in the 
purified vesicular fraction, which was further employed 
for isolation of the vesicle-associated 130 kDa glycopro- 
tein. 
The protein composition of the purified biliary vesi- 
cles was analyzed by SDS-PAGE, as shown in Fig. 1. 
As previously described [19,20], biliary vesicles (lane 3) 
had a characteristic protein profile composed of 130, 
114,86,62-67 and 52 kDa polypeptides, which is clearly 
distinctive from the protein pattern of whole bile and 
the micellar fraction (lane 1 and lane 2, respectively). 
The 130 kDa vesicular polypeptide was isolated by 
electroelution of the protein band excised from poly- 
acrylamide gels. The purification of the electroeluted 
130 kDa glycoprotein was evaluated by re-electrophore- 
sis and silver staining (lane 4). After the isolation proce- 
dure, the 130 kDa protein was qualitatively the only 
band detected, without presence of the others vesicular 
proteins. 
The identification of the 130 kDa vesicular glycopro- 
tein isolated from purified biliary vesicles was per- 
formed by direct amino acid sequencing and protein 
data bank searching. As shown in Fig. 2, there was a 
complete identity between the 130 kDa vesicular 
glycoprotein sequence and the previously reported 
amino acid sequence of the human intestinal aminopep- 
tidase-N [29]. The determined sequence corresponds to 
the cytoplasmic region and the transmembrane hydro- 
86 
phobic domain of this plasma membrane-associated c- 
toenzyme [30]. 
To measure the biliary concentration of aminopepti- 
dase-N by quantitative immunoblotting, rabbit polyclo- 
nal antibodies were prepared against the 130 kDa 
glycoprotein isolated from biliary vesicles. The immune 
serum exclusively recognized its specific antigen in 
Western blot assays of purified biliary vesicles, without 
a positive reaction with the other vesicle-associated pro- 
teins (result not shown). In five human hepatic biles, the 
mean concentration of aminopeptidase-N was 40 @ml 
(range from 17.3-57.6 @ml). This amount represents 
about 0.8% of the total biliary protein concentration 
(Table I). These measurements of biliary aminopepti- 
dase-N were further considered to design the appropri- 
ate experiments to analyze the effect of this protein on 
in vitro cholesterol nucleation time assays. 
Prior to the cholesterol nucleation time experiments, 
purified biliary aminopeptidase-N was obtained in na- 
tive conditions by purification and renaturation proce- 
dures of the 130 kDa glycoprotein isolated from SDS- 
PAGE of biliary vesicles. Renaturation of the purified 
aminopeptidase-N was demonstrated by testing the 
presence of its specific enzymatic activity. Aminopepti- 
dase-N specific activity was 2.47 mu&g under re- 
natured conditions after purification from biliary vesi- 
cles. 
Finally, the putative cholesterol crystallization-pro- 
motin activity of the vesicle-associated aminopeptidase- 
N was assessed by measuring its effect on the cholesterol 
crystal observation time of artificial model bile. Re- 
natured aminopeptidase-N was added to supersatu- 
rated model bile at increasing protein concentrations 
(from 1 to 20 pg/ml) in the assays. As represented in Fig. 
3, biliary aminopeptidase-N showed a concentration- 
dependent promoting effect on the cholesterol crystal 
observation time. The nucleation time was significantly 
correlated (r = -0.74, P < 0.001) in a reciprocal manner 
with the concentration of aminopeptidase-N used in 
these experiments. Because the low yield of the purifica- 
tion procedure to obtain sufficient amount of biliary 
aminopeptidase for nucleation time assays, we used 
Biliafy vesicle 
130 1Da glycopf otein 
AKGFY ISKSLGILGILL 
MAKGFYISKSLGILGILLGVAAVCTIIALSVVYS 
10 20 30 
Human intestinal 
aminopeptidase-N 
Fig. 2. Amino acid sequence of the amino-terminus of the biliary 
vesicle-associated 130 kDa glycoprotein. Amino acid sequencing was 
performed directly from the 130 kDa vesicular glycoprotein electro- 
blotted to a PVDF membrane. For comparison, the amino acid se- 
quence of the human intestinal aminopeptidase-N isalso shown [29]. 
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Fig. 3. Effect of aminopeptidase-N on the cholesterol crystal observation time of supersaturated model bile. Renatured biliary aminopeptidase-N 
and porcine kidney aminopeptidase-N (inset) were added at increasing protein concentrations. The cholesterol crystallization influencing activity 
is represented on the ordinate by the ratio between the nucleation time (in days) of assays with aminopeptidase-N (Ns) and the nucleation time 
of the respective control assays (NC). The nucleation time of the control model biles varied from 9 to 12 days (10 f 1 days, mean f 1 SD.). Then 
a N4Nc ratio less than 0.8 was considered as a significant cholesterol nucleation promoting activity of aminopeptidase-N. 
commercial available porcine kidney aminopeptidase-N 
(Sigma Chemicals Co., St. Louis, MO, USA) to analyze 
its effect on the cholesterol crystallization time at a 
concentration range commonly found in hepatic and, 
presumably, in gallbladder bile. It was assumed that the 
gallbladder bile concentration of aminopeptidase-N is 
ten times higher than the concentration measured in 
hepatic bile. As shown in the inset of Fig. 3, porcine 
kidney aminopeptidase-N also showed a significant 
concentration-dependent cholesterol crystallization 
promoting effect at a range concentration presumably 
present in human gallbladder bile (r = -0.76, 
P < 0.001). 
4. DISCUSSION 
The present study demonstrates that one of the hy- 
drophobic glycoproteins associated to native biliary 
vesicles is aminopeptidase-N, which possessed an in 
vitro concentration-dependent cholesterol crystalliza- 
tion activity. 
The 130 kDa vesicular glycoprotein was identified as 
aminopeptidase-N by amino acid sequencing and spe- 
cific enzymatic assay. The amino acid sequence analysis 
revealed that this protein is present in bile as a whole 
molecule, including its hydrophobic transmembrane 
domain [29]. This finding is consistent with the evidence 
that most of the biliary aminopeptidase-N is hydropho- 
bic [28] and with our previous report that the 130 kDa 
vesicular glycoprotein is partitioned into the detergent 
phase during Triton X-l 14 phase separation assays [20]. 
These experimental data allow us to postulate that 
aminopeptidase-N may be associated to biliary vesicles 
as a transmembrane protein, with its hydrophobic re- 
gion (from Leu-1 1 to Val-32) inserted into the lipid 
bilayer core of the cholesterol-phospholipid unilamellar 
vesicles. 
Aminopeptidase-N has been localized in the canalicu- 
lar plasma membrane domain of the hepatocyte [31,32]. 
Although it has been suggested that canalicular ectoen- 
zymes could be secreted into bile by a direct detergent 
effect of bile salts [33], the cellular mechanisms involved 
in the secretion of biliary aminopeptidase-N remain to 
be elucidated. 
The major finding of this study was that aminopepti- 
dase-N promoted in vitro cholesterol crystallization in 
a dose-dependent manner when it was added to artificial 
supersaturated model bile, using a concentration range 
present in human hepatic bile and, presumably, in na- 
tive gallbladder bile. In a preliminary report, Offner et 
al. have also shown that biliary aminopeptidase-N pos- 
sessed a cholesterol pronucleating effect [6]. We think 
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that aminopeptidase-N could represent he well-charac- 
terized, but still unidentified, potent cholesterol nuclea- 
tion-promoting protein previously described by Groen 
et al. [5]. Further immunological and protein analysis 
of the biliary 130 kDa concanavalin A binding protein 
are required to examine this possibility. 
The molecular mechanisms involved in the cholest- 
erol crystallization promoting activity of aminopepti- 
dase-N are presently unknown. In artificial cholesterol- 
rich phosphatidylcholine vesicles, it has been shown 
that cholesterol phase-separated domains reduce repul- 
sive hydration and steric forces between vesicles and 
generate discontinuity and point defects in the lipid 
membrane inducing vesicle aggregation and fusion, re- 
spectively [34,35]. It can be hypothesized that the hydro- 
phobic domain, inserted in the lipid bilayer of biliary 
vesicles, may play a critical role in the cholesterol pro- 
nucleating effect of biliary aminopeptidase-N. This hy- 
drophobic amino acid stretch could be interacting with 
either cholesterol or phospholipids of the vesicular 
membrane providing an appropriate local environment 
for cholesterol phase separation within the plane of the 
lipid bilayer, leading to crystal formation and growth. 
The demonstration of in vitro pronucleating activity 
of biliary aminopeptidase at concentrations usually 
found in native bile and the quantitation of aminopepti- 
dase-N in abnormal bile from cholesterol gallstone pa- 
tients represent wo initial key steps in the elucidation 
of the putative role of aminopeptidase-N in the patho- 
genesis of cholesterol gallstones. In a preliminary study, 
we have also shown that there is a significant reciprocal 
correlation between the concentration of biliary amin- 
opeptidase-N and the cholesterol crystal observation 
time in native gallbladder bile of cholesterol gallstone 
patients [36]. This suggestive result represents another 
necessary, but not sufficient, criteria for supporting a 
definitive role aminopeptidase-N in the pathogenesis of 
cholesterol gallstones. The next steps are to look for 
quantitative or qualitative differences of biliary amin- 
opeptidase-N between patients with and without gall- 
stones and to define the relative relevance of this 
cholesterol pronucleating glycoprotein as compared 
with other biliary pronucleating factors. Thus, further 
investigations are required to determine the significance 
of the biliary aminopeptidase-N in the pathophysiology 
of cholesterol gallstone disease. 
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